You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Management of Harlequin Ichthyosis: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor: Maria Tsivilika , Dimitrios Kavvadas , Sofia Karachrysafi , Antonia Sioga , Theodora Papamitsou

Harlequin ichthyosis (HI) is a life-threatening genetic disorder that largely affects the skin of infants. HI is the most severe form of the autosomal recessive disorder known as ichthyosis. It is caused by mutations in the A12 cassette (lipid-transporter adenosine triphosphate-binding cassette A12). Neonates affected by this disease are born with specific morphological characteristics, the most prominent of which is the appearance of platelet keratotic scales separated by erythematous fissures. The facial features include eclabium, ectropion, a distinct flattened nose, and dysplastic ears. A common finding among those with HI is impaired skin barrier function.

  • ichthyosis
  • Harlequin ichthyosis
  • keratinization
  • surgical management
  • treatment

1. Introduction

The pathological condition known as Harlequin ichthyosis (HI) is a severe but extremely rare form of congenital ichthyosis. This disorder affects significantly the process of keratinization. During the keratinization procedure, the epidermal skin layer differentiates to form the stratum corneum [1][2][3][4]. Epidermal keratinization begins approximately between the 20th and 24th week of the gestational period [5]. Thus far, it is known that HI is caused mostly by the truncation of ABCA12 gene mutations [6]. This specific gene is responsible for the regulation of lipid-transporting proteins in the epidermis. Mutations cause severe imbalances to the homeostasis of the stratum corneum [7]. Scientists are making efforts to identify all the possible mutations that are responsible for the clinical manifestation of HI. A recent case study suggested that the phenotype of HI is specifically determined by the novel ABCA12 mutation, p.Gly-1508Val [8]. Another recent case study found novel deleterious intronic variants that could lead to the most severe manifestations of the disease [9].
The prevalence of the disorder is approximately 1 out of 300,000 infants [4]. There is no significant association between sex and race with the incidence of HI [4]. Until recently, fetuses affected by HI were either stillborn or died as newborns a few days after birth. Thankfully, in the last two decades, the use of advanced therapy protocols, such as retinoids and novel procedures, has allowed several infants to exceed this narrowed period of time and survive longer [1][2][3][4].
There are three distinct subtypes of HI (Table 1). The differentiation among these subtypes is based mostly on the reported skin abnormalities. The abnormalities on the lamellar structure of the epidermis are caused not only by the dysregulation of the lipid transportation but also by the severe desquamation due to the hydrophobic nature of the lipids. These anomalies are caused by the loss of the normal function of the ABCA12 gene [10][11]. The skin is sensitive to epidermal “fractures” and to excessive fissures’ formation due to the significant lack of connective substance [10][11].
Table 1. Main types of Harlequin ichthyosis.

Type of HI

Keratin Expression

Keratohyalin Granules

Profilaggrin

Filaggrin

I

Normal

Normal in appearance

Yes

No

II

Types K6/K16 present, types K1/K10 reduced

Small and round like, anomalous

Yes

No

III

Normal

Absent in interfollicular epidermis

Expressed in intradermal sweat ducts, barely present in interfollicular epidermis

No
The first common abnormality is the irregular formation of the lamellar granule structure, which appears as a shortness of aberrant granules. Additionally, lipid droplets are detected in the vacuoles and the stratum corneum. The abnormal lamellar form can lead to extreme water reduction due to the hydrophobic properties of lipids. Another common irregularity is the abnormal conversion of profilaggrin to filaggrin. This atypical conversion leads to the excessive production of filaggrin and the inability to form a strong keratin complex. Other severe irregularities entail the expression of keratin and the detection of keratohyalin granules, either regular or irregular [11][12][13][14].
The abovementioned abnormalities can negatively affect the desquamation process and lead to the distinguish characteristics of the disease; an armor-like thick and fissured stratum corneum [14]. Further evidence suggests that calcium may be related to the development of HI because of its significant role in the differentiation of the epidermis [14][15]. Calpains are a distinctive form of proteolytic enzymes, activated by calcium. There is indication that these enzymes are essential for the signal transduction processes during differentiation [14][15].
The literature reports a variety of symptoms that are related to HΙ. The most prominent and conspicuous ones are responsible for the name of the disease: brown or white skin, grooved or cracked, eclabium, ectropion, nasal hypoplasia, lack of external ears, sparse scalp hair, short limbs, hypoplastic digits, and complete absence of eyebrows and eyelashes [13][14]. Hypoventilation, respiratory failure, and respiratory depression are also reported among the symptoms, attributed to the confinement of the pectoral wall by the armor-like skin. In addition, there are central nervous system traits of the disease, such as seizures, that raise concerns [16]. Due to the cracked skin, infants also suffer excessive dehydration which can lead to severe metabolic dysregulation. Finally, infants face significant feeding problems and gastrointestinal disorders, leading to malnutrition [16].
A detailed family history record is quite valuable, as it could lead to the identification of a variety of possible risk factors such as genetic reports, siblings affected by the disease, consanguinity, and history of other abnormalities that affect keratotic skin [17]. The genetic pathology of Harlequin ichthyosis has been well known in the literature for several years and has also been shown in the official classification of inherited ichthyoses [17]. A common clinical method used for the diagnosis of HI is ultrasonography [18]. Diagnosis can also be made by either 2D or 3D ultrasonography according to the manifestation of specific symptoms (i.e., cystic formation in front of the eyes, limb anomalies, and hypoechogenic amniotic fluid). Until the identification of the ABCA12 gene, a fetal skin biopsy was the preferred method of prenatal diagnosis, performed at the 20–24th week of gestation. It should be noted that light microscopy may also give a falsely negative outcome during the interpretation of the biopsy samples, based on the sites of the tissue collection [19][20]. Nowadays, the standard technique for the detection of HI is next-generation sequencing (NGS). Nevertheless, clinical investigation and ultrasonography are, in most cases, adequate and, therefore, necessary for a safe diagnosis [21].
Regarding the surgical management of HI, the case studies presented in the literature are limited. Surgical cases offer valuable knowledge, focusing on digital ichthyosis, a common manifestation among HI patients, which threatens the neurovascular integrity of the upper limbs [6][22]. Circumferential release and subsequent Z-plasty reconstruction result in beneficial outcomes in cases of congenital constriction bands [6][22]. It is essential to assess the surgical management of HI and, therefore, emphasis was given to surgical reports.
Apart from the management of the disease, parents should be given appropriate support by social workers and psychologists. As most infants do not survive the neonatal period, it is crucial for the family to cope with the possibility of their probable loss [23]. In addition to the NICU (Neonatal Intensive Care Unit), the infant has to face a number of surgical procedures, such as reconstructive surgery and skin grafts, in order to manage the skin injuries and to treat the extremities and the eyelids [2][24]. Inevitably, the infant’s quality of life will be seriously affected due to the constant medical follow ups and medication intake [25][26]. There is also high probability for these children to develop psychological disorders, mainly due to the fact of their appearance [25][26].

2. Management of Harlequin Ichthyosis

HI is a severe but rare disorder that is fatal for newborn infants. In order to deal with this unique medical challenge and increase the survival rates, a multidisciplinary team of physicians, among other experts, is essential. Researchers have already focused on the genetical aspect of the disease. Despite knowledge of the responsible gene, the mutations present several disparities among each case, leading to a variety of symptoms and affecting the survival rates. Utter comprehension of ABCA12 gene mutations is vital for managing the disorder. The pathophysiological mechanisms responsible for the disease’s manifestation are associated with the mutations created in the genome and, therefore, researchers suggest that this knowledge will increase the survival rates after birth [6][7][8][9].
The affected patients will face several challenges, especially during the neonatal period. In order to deal with this dire situation, genetic investigation is not enough. It is essential for physicians to have at hand effective guidelines, confirmed by the international literature. As time is of the essence, proper instructions could make the difference. The limited literature resources for HI led physicians to the implementation of managing methodologies and treatments from other ichthyosis cases or even similar dermatological disorders. In regard to surgical preparation and management, there have already been many approaches. Admission to an NICU should not be avoided and increased humidity is essential. Applying topical retinoids has been suggested as alternative to surgery but with no satisfactory results in most cases. Moreover, their combination with surgery did not manage to control the relapse of the disease. Alternatives, such as vitamin D intake, should be considered in order to avoid the retinoids’ side effects and investigate further the possibility of better outcomes.
Limb encasement and constriction may also lead to autoamputation due to the presence of tissue necrosis. Therefore, confirmation of any possible limb confinement should be a reminder for surgical assessment. Operation using local anesthesia mitigates risk related to airway obstruction; however, parental counseling before the surgical procedure should include information regarding possible complications, due to the possibility of infections, and other recovery plans.
Nowadays, novel research focuses on the immune system and the full characterization of the immunological profiling of these patients, as it may lead to therapeutic approaches that have not yet been implemented [27]. Other skin disorders, such as psoriasis and atopic dermatitis, share the same immune characteristics as HI. For instance, the immunoactivity is similar to the allergic reactions including IL-17 signaling. The scientific community should investigate further the possibility of immunotherapy, such as monoclonal antibodies.
Another novel perspective is the topical application of enzymes that are involved in desquamation [11]. Kallikrein proteases were found on experiments with mice to mitigate the hyperkeratosis when topically applied. This evidence suggests that the lack of proteolytic enzymes due to presence of ABCA12 gene mutations could be the main culprits in the pathophysiology of HI.
Cooperation with parents is also essential in order to avoid serious predicaments [28]. It is vital for the survival of the infant that parents understand the situation and the possible options (both pharmaceutical and surgical) in order to avoid behaviors that may endanger the child further.
At the moment, the most common surgical interventions are autologous skin grafts. However, because of the high possibility of sepsis and bacterial infections in the epidermis and the skin layer, invasive procedures should be treated with extreme caution. On the other hand, for some cases, such as nasal occlusion, endotracheal intubation is unavoidable [22][29]. Therefore, it is an undeniable fact that HI surgical and general management can be quite challenging and specific guidelines will make the difference.

This entry is adapted from the peer-reviewed paper 10.3390/children9060893

References

  1. Ahmed, H.; O’Toole, E.A. Recent advances in the genetics and management of harlequin ichthyosis. Pediatric Dermatol. 2014, 31, 539–546.
  2. Craiglow, B.G. Ichthyosis in the newborn. In Seminars in Perinatology; WB Saunders: Philadelphia, PA, USA, 2013; Volume 37, pp. 26–31.
  3. Glick, J.B.; Craiglow, B.G.; Choate, K.A.; Kato, H.; Fleming, R.E.; Siegfried, E.; Glick, S.A. Improved management of harlequin ichthyosis with advances in neonatal intensive care. Pediatrics 2017, 139, e20161003.
  4. Enjalbert, F.; Dewan, P.; Caley, M.P.; Jones, E.M.; Morse, M.A.; Kelsell, D.P.; O’Toole, E.A. 3D model of harlequin ichthyosis reveals inflammatory therapeutic targets. J. Clin. Investig. 2020, 130, 4798–4810.
  5. Rathore, S.; David, L.S.; Beck, M.M.; Bindra, M.S.; Arunachal, G. Harlequin ichthyosis: Prenatal diagnosis of a rare yet severe genetic dermatosis. J. Clin. Diagn. Res. JCDR 2015, 9, QD04.
  6. Elkhatib, A.M.; Omar, M. Ichthyosis Fetalis; StatPearls: Treasure Island, FL, USA, 2021.
  7. Arias-Pérez, R.D.; Gallego-Quintero, S.; Taborda, N.A.; Restrepo, J.E.; Zambrano-Cruz, R.; Tamayo-Agudelo, W.; Bermúdez, P.; Duque, C.; Arroyave, I.; Tejada-Moreno, J.A.; et al. Ichthyosis: Case report in a Colombian man with genetic alterations in ABCA12 and HRNR genes. BMC Med. Genomics 2021, 14, 140.
  8. Miyazaki, M.; Ohkawa, N.; Miyabayashi, K.; Shoji, H.; Takeichi, T.; Kantake, M.; Akiyama, M.; Shimizu, T. Case of harlequin ichthyosis in preterm infant with a compound heterozygous ABCA12 missense mutation. J. Dermatol. 2022, 49, 137–139.
  9. Sheth, J.J.; Bhavsar, R.; Patel, D.; Joshi, A.; Sheth, F.J. Harlequin ichthyosis due to novel splice site mutation in the ABCA12 gene: Postnatal to prenatal diagnosis. Int. J. Dermatol. 2018, 57, 428–433.
  10. Shibata, A.; Akiyama, M. Epidemiology, medical genetics, diagnosis and treatment of harlequin ichthyosis in Japan. Pediatr. Int. 2015, 57, 516–522.
  11. Zhang, L.; Ferreyros, M.; Feng, W.; Hupe, M.; Crumrine, D.A.; Chen, J.; Roop, D.R. Defects in stratum corneum desquamation are the predominant effect of impaired ABCA12 function in a novel mouse model of harlequin ichthyosis. PLoS ONE 2016, 11, e0161465.
  12. Brandão, P.; Seco, S.; Loureiro, T.; Ramalho, C. Prenatal sonographic diagnosis of Harlequin ichthyosis. J. Clin. Ultrasound 2019, 47, 228–231.
  13. Koochek, A.; Choate, K.A.; Milstone, L.M. Harlequin ichthyosis: Neonatal management and identification of a new ABCA12 mutation. Pediatric Dermatol. 2014, 31, e63–e64.
  14. Scott, C.A.; Rajpopat, S.; Di, W.L. Harlequin ichthyosis: ABCA12 mutations underlie defective lipid transport, reduced protease regulation and skin-barrier dysfunction. Cell Tissue Res. 2013, 351, 281–288.
  15. Murase, C.; Takeichi, T.; Shibata, A.; Nakatochi, M.; Kinoshita, F.; Kubo, A.; Akiyama, M. Cross-sectional survey on disease severity in Japanese patients with harlequin ichthyosis/ichthyosis: Syndromic forms and quality-of-life analysis in a subgroup. J. Dermatol. Sci. 2018, 92, 127–133.
  16. Wang, X.; Cao, C.; Li, Y.; Hai, T.; Jia, Q.; Zhang, Y.; Zhao, J. A harlequin ichthyosis pig model with a novel ABCA12 mutation can be rescued by acitretin treatment. J. Mol. Cell Biol. 2019, 11, 1029–1041.
  17. Oji, V.; Tadini, G.; Akiyama, M.; Bardon, C.B.; Bodemer, C. Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Sorèze 2009. J. Am. Acad. Dermatol. 2010, 63, 607–641.
  18. Shruthi, B.; Nilgar, B.R.; Dalal, A.; Limbani, N. Harlequin ichthyosis: A rare case. Turk. J. Obstet. Gynecol. 2017, 14, 138.
  19. Tontchev, G.; Silverberg, N.B.; Shlasko, E.; Henry, C.; Roberts, J.L.; Roth, M.Z. Techniques for toddlers: Linear band incision for harlequin ichthyosis with associated compartment syndrome. Pediatric Dermatol. 2014, 31, 625–629.
  20. Hoffmann, A.; Metzger, J.; Wöhlke, A.; Peters, M.; Junginger, J.; Mischke, R.; Distl, O.; Hewicker-Trautwein, M. Congenital Ichthyosis in 14 Great Dane Puppies with a New Presentation. Vet. Pathol. 2016, 53, 614–620.
  21. Londhe, M.M.; Patil, T.V.; Suryawanshi, K.H. Harlequin fetus: A case report. Indian J. Pathol. Microbiol. 2022, 65, 462–464.
  22. Gatmaitan-Dumlao, J.K.G.; Tababa, E.J.L.; Jao-Tan, C.; Frez, M.L.F. Harlequin Ichthyosis in a Filipino Newborn: Management Pearls in a Resource-limited Setting. Acta Med. Philipp. 2021, 55.
  23. Abeni, D.; Rotunno, R.; Diociaiuti, A.; Giancrisoforo, S.; Bonamonte, D. The Burden of Autosomal Recessive Congenital Ichthyoses on Patients and their Families: An Italian Multicentre Study. Acta Derm. Venereol. 2021, 101, adv00477.
  24. Auriti, C.; Rotunno, R.; Diociaiuti, A.; Manzoni, S.M.; Uva, A.; Bersani, I.; El Hachem, M. Juvenile idiopathic arthritis in infants with Harlequin Ichthyosis: Two cases report and literature review. Ital. J. Pediatrics 2020, 46, 1–6.
  25. Washio, K.; Sumi, M.; Nakata, K.; Fukunaga, A.; Yamana, K.; Koda, T.; Yamanishi, K. Case of harlequin ichthyosis with a favorable outcome: Early treatment and novel, differentially expressed, alternatively spliced transcripts of the ATP-binding cassette subfamily A member 12 gene. J. Dermatol. 2017, 44, 950–953.
  26. Liu, J.; Zhang, X.; Wang, W.; Lan, X.; Dong, M.; Yan, K.; Jin, C. Case Report: Prenatal Diagnosis of a Fetus with Harlequin Ichthyosis Identifies Novel Compound Heterozygous Variants: A Case Report. Front. Genet. 2021, 11, 1756.
  27. Akiyama, M. Understanding immune profiles in ichthyosis may lead to novel therapeutic targets. J. Allergy Clin. Immunol. 2022, 149, 1210–1212.
  28. Sereke, S.G.; Berhe, S.E.; Bongomin, F. Harlequin fetus: A mayhem in a consanguineous marriage? Clin. Case Rep. 2021, 9, e04540.
  29. Sitek, J.C.; Merckoll, E.; Tølløfsrud, P.A. Osteopenia and multiple fractures in an infant with harlequin Ichthyosis. JAMA Dermatol. 2018, 154, 847–849.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Academic Video Service
Feedback